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Background/aim: Psoriasis is a chronic skin disease. To reduce side effects associated with current treatment modalities, new treatment
methods are required. Some clinicians have begun to use microphototherapy to treat psoriatic patients with a limited number of lesions
(lesions affecting <10% of the body surface area).
Materials and methods: Microphototherapy is indicated in patients whose lesions persist despite systemic and topical treatment or
when such treatment is contraindicated. Our study aimed to evaluate the efficacy of microphototherapy in psoriasis patients with
localized lesions. Patients in this unblinded and prospective study were treated three times a week for 50 sessions using a MedLight
CupCUBE Grimed microphototherapy device that emits an ultraviolet B (UVB) spectrum.
Results: Forty-five lesions in 23 psoriatic patients were treated. Treatment outcome was evaluated based on the Psoriasis Severity Index
(PSI). PSI scores decreased significantly during the treatment.
Conclusion: The MedLight CupCUBE Grimed microphototherapy device was effective for the treatment of psoriasis patients with
localized lesions. The device can administer UVB radiation to involved regions while protecting uninvolved regions and minimizing
radiation dose. However, having to be administered by experienced technicians and the long time required for each treatment session
are disadvantages of the technique.
Key words: Psoriasis, phototherapy, treatment

1. Introduction
Phototherapy is an important therapeutic modality
commonly used for dermatological treatment. During
the last two decades, there have been significant
technological advancements in phototherapy. A
new technique referred to as targeted phototherapy,
concentrated phototherapy, focused phototherapy, or
microphototherapy can be considered among the most
important of such advancements. The disadvantages of
conventional phototherapy devices include irradiation
of unaffected areas and multiple frequent visits to
clinics. It is also difficult to treat children and to treat
such regions as genitalia and oral mucosa with these
devices. Microphototherapy devices facilitate treatment
of affected regions while protecting nonaffected regions.
Additionally, these devices can reduce the number of
treatment sessions and total duration of the treatment
with increasing patient satisfaction. As opposed to
conventional phototherapy, microphototherapy can
* Correspondence: drnesli23@hotmail.com
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be easily administered to genitalia, oral mucosa, and
children (1). Several recent studies on the use of
microphototherapy alone or in combination with topical
drugs for the treatment of psoriatic patients have been
published (2–9). The present study aimed to evaluate the
efficacy of targeted UVB phototherapy using a MedLight
CupCUBE Grimed microphototherapy device in the
treatment of psoriasis patients with localized, plaquetype lesions.
2. Materials and methods
2.1. Patients
Patients who were admitted to the university hospital clinic
of dermatology were evaluated for the study. Patients aged
≥10 years with chronic, plaque-type psoriasis and lesions
affecting ≤10% of the body surface area were included
in this prospective and unblinded study. Patients were
included in the study providing that they did not receive
systemic therapy such as methotrexate, cyclosporine,
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biological agents, or any topical agent during the previous
month or oral retinoid treatment during the previous 6
months. Exclusion criteria were pregnancy, lactation, and
the presence of photosensitive disorders such as porphyria
and xeroderma pigmentosum. Based on these criteria, 27
patients with chronic, plaque-type psoriasis were included
in the study; however, 4 of the patients discontinued the
therapy.
2.2. Phototherapy device
Microphototherapy was administered using a MedLight
CupCUBE Grimed device, which uses nonexcimer
technology to deliver UV radiation (Figures 1a and 1b).
The light source was a 150-W high-pressure spherical
burner that emits both UVA and UVB radiation. To
benefit from the device’s UVA emission, a filter must be
placed on the device. However, only UVB radiation was

administered during the study. The spectral irradiance of
the device is shown in Figure 2. The light is concentrated
within the UVB wavelengths of 300–350 nm, with a peak
at 311 nm. The radiation field of the system varies from 10
mm to 40 mm. The UVB dose administered by the device
is 30 mJ/cm² at a distance of 1 cm.
2.3. Treatment protocol
All lesions were irradiated with narrowband UVB (NBUVB) phototherapy 1 cm away from the lesion. For lesions
>1 cm in diameter, the area was treated with multiple
applications side by side in accordance with the lesion
diameter. Regardless of skin phototype and lesion diameter,
the initial duration of treatment was 10 s and the initial
treatment dose was 300 mJ/cm2. The duration of treatment
was increased 2 s and the dose was increased 60 mJ/cm2 in
every session. The therapy was applied three times a week

b

a

Figure 1. The MedLight CupCUBE Grimed microphototherapy device (a) and its light-transmission cable and
distance adjustment bar (b).

Energy (%)

UVB

Wavelength (nm)

Figure 2. The UVB spectrum of the MedLight CupCUBE Grimed
microphototherapy device.
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on nonconsecutive days for 50 sessions in each patient. The
treatments were administered by a phototherapy technician.
To reduce the severity of scales of the plaques, the patients
were advised to apply solid petrolatum to the lesions on
nontreatment days and to wash the treatment areas before
UV irradiation. Just before each UV treatment session,
liquid petrolatum was applied to increase UV transmission.
The duration of each subsequent treatment session was
increased until mild/moderate erythema was observed.
When severe erythema or bulla was observed, the treatment
was not administered. During the subsequent treatment
session if erythema or bulla regressed, the treatment was
administered at the previous dose, but if no regression was
observed, the treatment was administered for 2 s less than
the previous session.
2.4. Assessment
The Psoriasis Severity Index (PSI) was used to evaluate
treatment outcome. PSI is a modified Psoriasis Area and
Severity Index (PASI) score used to assess erythema,
induration, and desquamation on a scale of 0–4 (0:
none; 1: mild; 2: moderate; 3: severe; 4: very severe).
The maximum possible total PSI score is 12. As opposed
to PASI, PSI ignores calculation of area; therefore, each
lesion is assessed individually and the PSI score only
provides information about a single lesion (5). However,
both patient- and lesion-based scores were evaluated in
this trial. If the patient had 2 or more lesions and these
were being treated, their PSI score was accepted as the
mean sum of the values for each lesion that was calculated
before treatment, at session 36, and at session 50. At the
end of session 50, PSI 50% (50% reduction in PSI score)
was accepted as the required minimum response. If
complete improvement was observed before session 50,
the treatment was terminated early, whereas therapy was
prolonged or switched to another treatment modality if
after session 50 the response to treatment was inadequate.
Treated plaques did not receive any topical or systemic
therapy during the study. During the course of treatment,
the largest diameter of each lesion was measured using a
ruler and standardized photographs were obtained using
a CanonEOS D450 digital camera at baseline and at
treatment sessions 12, 24, 36, and 50.
2.5. Statistical analysis and ethics committee and
Ministry of Health approval
SPSS v.21.0 for Windows (SPSS, Inc., Chicago, IL, USA)
was used for all statistical analyses. At the end of the study,
the primary endpoint was reduction in the PSI score.
When parametric assumptions were not provided, lesion
diameters and PSI scores were analyzed using Freidman’s
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test. If there was a significant difference, then Wilcoxon’s
test was used for pairwise comparison. Wilcoxon test
results were interpreted according to the Bonferronicorrected P value. Differences in numeric variables
between independent groups were analyzed by using the
Mann–Whitney U test when parametric assumptions were
not provided. The chi-square test was used to determine
whether there were differences in categorical variables
between independent groups. Relationships between the
quantitative variables were calculated using Pearson’s
correlation coefficient. The level of statistical significance
was set at P < 0.05.
This study received permission from Hacettepe
University Faculty of Medicine Local Ethics Committee
Clinical and Pharmaceutical Research on 22.11.2012 (Issue
number: 06-03). The present study also received approval
from the Ministry of Health with tracking number 806637
on 24.01.2013.
3. Results
The study included 23 patients of whom 13 (56.5%) were
female and 10 (43.5%) were male. The mean age of the
patients was 33.17 ± 13.22 years (10–62). Of all, 6 patients
had an additional systemic disease including asthma (n =
1), epilepsy (n = 1), inactive hepatitis B carrier (n = 1),
nonalcoholic steatohepatitis (n = 1), hypothyroidism (n =
1), and rheumatoid arthritis (n = 1). Among the patients,
8 patients had a family history of psoriasis in first- or
second-degree relatives. None of the patients had psoriatic
arthritis.
Totally, 45 lesions in the 23 patients were treated, 21
(46.7%) of which were localized on the elbow region, 17
(37.8%) on the knee, 3 on the abdominal region, and 1 each
on the thigh, leg, buttocks, and sacrum region respectively.
Localization of the lesions is shown in Figure 3. Eighteen
patients had multiple psoriatic lesions. In 11 of 18 patients,
the value of PSI scores in each lesion changed in different
proportions during the treatment sessions. However, the
changes in these scores did not seem to differ significantly.
As for the remaining 7 patients, despite more than one
lesion on the same patient, the lesions responded in the
same way to the treatment (Table 1).
The mean lesion diameter and PSI score at baseline
and at 4 time points during the course of treatment are
shown in Table 2. In terms of lesion diameter, there was no
improvement until session 36. In other words, there was no
significant improvement in lesion diameter between sessions
0 and 12, 12 and 24, 24 and 36, 0 and 50, 0 and 36, or 24 and
50; however, a significant decrease in lesion diameter was
observed between sessions 36 and 50 (P < 0.05).
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Figure 3. Localization of the 45 psoriatic lesions.

At the end of treatment session 50, the mean PSI score
for the 45 lesions decreased from 5.6 to 3.07 (Table 2) and
this difference was significant (P < 0.05). PSI scores at
baseline and at sessions 36 and 50 are shown in Figure 4.
The rate of PSI improvement for the 45 lesions was 31.71%
at session 36, followed by 45.7% at session 50 (Table 3).
Similarly, the rate of PSI decrease for the 23 patients was
45.8% at session 50 (Table 3). At the end of treatment
sessions, 4 of the 23 patients exhibited complete clearance
(PSI 100%, the percentage of decrease in the PSI score
is 100, Table 4). In contrast, in 3 patients the PSI score
never changed during the treatment sessions (PSI 0%, the
percentage of decrease in the PSI score is 0). The remaining
16 patients responded to the treatment in varying degrees,
but they did not reach the target PSI, 50%. However, they
were very close to the target with mean PSI change of
46.6% at the end of session 50. All in all, 14 (60.9%) of the
23 patients achieved PSI ≥ 50% (Table 4).
The only observed side effect of the microphototherapy
treatment was blister formation at session 45 and it was
seen only in 1 of the 23 patients (Figure 5).
4. Discussion
To the best of our knowledge, the literature does not
include any studies on the use of the MedLight CupCUBE
Grimed microphototherapy system for the treatment of
psoriasis or any other dermatological disease. It is known
that UVB suppresses the proinflammatory cytokine
pathway by decreasing interleukin (IL) 12, interferongamma (IFN-γ) and IL-8 expression, and can selectively

reduce proinflammatory cytokine production by T cells
(10). In contrast, since IL-4–producing T cells are resistant
to the cytotoxic actions of UVB, IL-4 levels increase in
psoriatic skin following UVB irradiation (11). Decreased
IFN-γ expression and increased in IL-4 production after
UVB irradiation lead to decreased local immunoreactivity,
which forms the therapeutic effects of UVB on psoriasis.
Moreover, UVB irradiation has inhibitory effects on the
IL-23/IL-17 axis, which exhibits an important pathway in
psoriasis pathogenesis (12). In conclusion, UVB therapy is
associated with downregulation of type 1 and type 2 IFN
signaling pathways (IL-12, IFN-γ, IL-8) and suppression of
the IL-23/IL-17 axis while immunosuppressive cytokines
as IL-4, IL-6, IL-10 increase.
Several studies have examined UV microphototherapy
for psoriasis, but the findings are inconsistent (2–9).
Asawanonda et al. (2) administered irradiation with
targeted UVB phototherapy (Dualight) in 13 patients
three times a week and reported clearance of localized
psoriatic lesions after 4 weeks of treatment. Lapidoth
et al. (3) achieved improvement using the BClear UV
device and UVB irradiation administered twice a week to
28 patients for 6–18 sessions (mean number of sessions:
10). They reported a decrease in PSI scores of 73% after
6 weeks and 63% after 16 weeks, and they concluded that
UVB microphototherapy was effective for the treatment
of psoriasis. Toll et al. (7) treated 15 patients with chronic
plaque psoriasis using the BClear Targeted PhotoClearing
System twice a week for a maximum of 13 sessions. The
mean Scaling Erythema Induration (SEI) score decreased
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Table 1. PSI scores for the 45 psoriatic lesions in 23 patients.
Number of patient

Lesion number

N1

2

N2

2

N3

1

N4

3

N5

1

N6

2

N7

2

N8

2

N9

1

N10

2

N11

4

N12

2

N13

1

N14

2

N15

2

N16

2

N17

3

N18

2

N19

2

N20

1

N21

2

N22

2

N23

2
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Lesion
L1
L2
L1
L2
L1
L1
L2
L3
L1
L1
L2
L1
L2
L1
L2
L1
L1
L2
L1
L2
L3
L4
L1
L2
L1
L1
L2
L1
L2
L1
L2
L1
L2
L3
L1
L2
L1
L2
L1
L1
L2
L1
L2
L1
L2

PSI 0
7
7
4
3
6
3
3
3
9
7
6
3
3
5
5
7
6
6
8
8
8
8
6
6
7
4
3
4
6
8
7
6
6
6
3
4
4
8
5
6
6
6
6
4
6

PSI 36
4
5
0
0
3
2
3
2
9
1
2
3
3
5
5
0
5
5
6
6
5
5
6
6
6
0
0
4
4
5
5
3
5
4
0
1
6
6
5
6
7
5
5
4
4

PSI 50
4
4
0
0
3
2
2
2
7
0
2
3
3
5
5
0
3
4
4
4
5
3
3
3
5
0
0
3
4
4
4
5
4
4
0
1
0
0
5
6
6
5
5
3
3
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Table 2. Mean diameter and mean PSI scores for the 45 psoriatic lesions.
Number of
sessions

Diameter (cm)
(mean ± SD)

PSI
(mean ± SD)

0

3.85 ± 1.59

5.60 ± 1.72

12

4.00 ± 1.57

24

3.95 ± 1.92

36

3.94 ± 2.31

3.89 ± 2.18

50

3.31 ± 2.39

3.07 ± 1.94

Figure 4. PSI scores at baseline, session 36, and session 50.
Table 3. The percentage of decrease in the mean PSI score for the 45 psoriatic lesions and in the 23 patients.
Range of
sessions

PSI decrease (%) in 45 lesions
(mean ± SD)

PSI decrease (%) in 23 patients
(mean ± SD)

0–36

31.71 ± 36.21

33.05 ± 35.78

36–50

18.50 ± 31.24

15.00 ± 23.74

0–50

45.65 ± 33.12

45.75 ± 34.17

from 5.7 to 3.0 after a month of treatment. They concluded
that UVB microphototherapy is an efficient and safe
method for treating persistent plaques in psoriatic patients
while sparing healthy skin regions. In 2011, Nishida
published the results of targeted NB-UVB phototherapy
using a flat-type lamp in 6 psoriasis patients with resistant

plaques. They applied therapy with an initial dose of 70%
of the minimal erythema dose, with a 20% increase at each
subsequent session once or twice a week. At the end of the
study, they reported that all lesions of the tested patients
were responsive to NB-UVB phototherapy using the flattype lamp (8).
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Table 4. The mean PSI decrease according to the patients.
23 patients

The mean PSI decrease

3 of 23 patients

0%

4 of 23 patients

100%

6 of 23 patients

<50%

10 of 23 patients

≥50%

Figure 5. Blister formation in a psoriasis patient.

To increase the efficacy of microphototherapy, it can be
combined with other therapies. Ozkan et al. (6) investigated
the efficacy of adding topical therapies to microphototherapy
in 30 patients with psoriasis. The patients were randomly
divided into 3 groups: microphototherapy alone, psoralen
gel plus microphototherapy, and calcipotriol plus
microphototherapy. The researchers reported that the
addition of calcipotriol ointment to microphototherapy
enhanced the therapeutic effects of phototherapy in the
treatment of patients with plaque-type psoriasis. In another
trial, Amornpinyokeit et al. included 10 stable psoriasis
patients who were randomized to receive either targeted NBUVB alone or 8-methoxypsoralen (8-MOP)/NB-UVB to two
separate areas within the same lesion. The improvement in
disease activity as reflected by PSI score during the treatment
was significantly better in the combination group. The mean
remission time of lesions that were cleared by 8-MOP/NBUVB was 8 weeks, while it was 4.67 weeks in lesions that were
cleared by NB-UVB alone. Thus they concluded that addition
of 0.1% 8-MOP cream to targeted NB-UVB significantly
enhances the therapeutic effects of the light treatment
without increasing the incidence of adverse effects (9).
Excimer lasers, excimer nonlasers, and monochromatic
excimer nonlaser light (MEL) sources are the other
microphototherapy methods. There are several studies
on these devices. In a study with a large group of patients,
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Feldman provided data on 51 subjects who obtained
at least 75% improvement in the lesions with 308-nm
excimer laser treatment. They reported that 308-nm
excimer laser treatments appear to offer relapse-free
periods for psoriasis patients with localized lesions that
are comparable or better than those offered by standard
topical therapy regimens (13). MEL sources can be used to
treat mild to moderate psoriasis, palmoplantar psoriasis,
and palmoplantar pustular psoriasis (14,15).
Treatment with microphototherapy can cause various
tolerable adverse effects including erythema, blistering,
hyperpigmentation, erosion, burning, and itching (3,6,16–
18). Therefore, in the present study the patients were asked
about the occurrence of any of these side effects. According
to the patients, the radiation was generally well tolerated.
The only observed side effect was blistering in 1 patient
and thus dose escalation was performed until session 50
in 22 patients. Dose escalation was used in order to ensure
that as many of the patients as possible would benefit from
the treatment. As a result, 60.9% of the patients had an
improvement (the percentage of decrease in the PSI score
is ≥50%). Moreover, 4 of the 23 patients had complete
clearance (the percentage of decrease in the PSI score is
100%) at the end of treatment.
The study has some limitations. Firstly, the minimal
erythema dose was not calculated. A standard therapy dose
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and a standard duration of treatment were administered to
all patients. Therefore, beginning the treatment with a low
UVB dose might increase the number of sessions. Having a
small number of patient groups and lacking a control group
are the other limitations. Due to the fact that the treatment
was time consuming and laborious and it required coming
to the hospital three times a week, 4 patients who initially
participated to the treatment apart from our study group
of 23 patients discontinued the treatment.
In conclusion, the present findings show that targeted UVB
radiation administered using a MedLight CupCUBE Grimed
microphototherapy device at an emission range of 300–350
nm and a peak of 311 nm was effective for the treatment of
psoriatic plaques. Furthermore, the findings indicate that
targeted UVB phototherapy is an effective treatment option
in psoriasis patients who do not benefit from topical therapy
and who have limited numbers of lesions. In particular,

microphototherapy eliminates exposing unnecessarily large
areas of the body to radiation; however, this therapy must be
administered by experienced technicians/clinicians. Thus,
microphototherapy is more expensive and time-consuming
than other treatment methods, especially in patients with
lesion diameter >1 cm who require multiple treatment
sessions. In addition, microphototherapy requires patients to
come to the hospital at least twice a week. As a result of these
challenges, we recommend the addition of topical therapies
(topical corticosteroid, topical calcipotriol, topical retinoid,
topical immunomodulator) to microphototherapy as a way
to decrease the number of in-hospital sessions. We think
microphototherapy is especially appropriate for patients with
psoriasis who do not benefit from topical therapy, for those
who develop side effects due to such treatment, for those of
whom topical therapy is contraindicated, and for those with
lesions that cannot be easily reached.
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